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Summary
Objective: To assess whether beta-2 microglobulin (B2M) has effects on articular chondrocytes that would implicate B2M involvement in
osteoarthritis (OA) pathogenesis.
Methods: The mRNA levels of B2M in fetal and osteoarthritic chondrocytes were detected by RT–PCR. B2M levels in synovial fluid and tissue
cultured media from cartilage explants were tested using B2M ELISA kit. Primary cultured chondrocytes were used for proliferation and
microarray experiments.
Results: The average B2M level in OA synovial fluid is significantly higher than that found in normal synovial fluid. However, there was no
significant difference in B2M synovial fluid levels amongst differing OA stages. The release of B2M by osteoarthritic cartilage was detectable
after 24 h in culture and continued to increase during the 72 h study period. B2M had an inhibitory effect on chondrocyte growth at 1.0 g/ml,
and became significantly inhibitory at 10.0 g/ml. Genes regulated by B2M were detected through microarray technology. Twenty genes
were found to be up-regulated by B2M, including collagen type III which is known to be up-regulated in OA. Eleven genes were found to be
down-regulated at least two-fold by B2M.
Conclusion: These results indicate that B2M is highly expressed in OA cartilage and synovial fluid compared to normal, and suggest that
B2M may have effects on chondrocyte function that could contribute to OA pathogenesis. © 2002 OsteoArthritis Research Society
International. Published by Elsevier Science Ltd. All rights reserved.
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Beta-2 microglobulin (B2M) is a non-glycosylated single
polypeptide chain. It is composed of 119 amino acids and
has a molecular weight of 11 800 Da1. B2M is synthesized
by all nucleated cells and is normally expressed on the cell
surface as an integral part of the major histocompatibility
class I complex HLA. It can also exist in a non-HLA-
associated form2,3. As HLA molecules are continuously
turned over, B2M is shed from the cell membrane into blood
and eventually catabolized in the kidney4. Normally, the
serum concentration of B2M is less than 2 mg/litre (or
2 g/ml)5.
Increased serum levels of B2M have been found in
inflammatory and malignant diseases, including rheumatic
disorders, infectious diseases and lymphoproliferative
disorders6–8. Studies have shown that serum levels of B2M
can be used as a non-specific marker for certain systemic
disease activities and to monitor the effectiveness of thera-
peutic interventions5,9. A significant decrease in the serum950levels of B2M was observed after alendronate treatment in
rheumatoid arthritis10. Although B2M has been associated
with the immunogenetic system and regarded as a useful
marker for monitoring inflammatory and malignant disease
activity, its exact function remains unclear.
In addition to its involvement in the immune system, B2M
activity has also been associated with osteo-articular tissue
in hemodialysis-associated amyloidosis (HAA or B2M amy-
loidosis)11,12. HAA is a complication found in long-term
hemodialysis patients. It comprises a wide spectrum of
clinical manifestations, including arthritis13,14. Amyloid
fibrils containing B2M have been demonstrated in
joint capsules, synovium, articular cartilage and bone in
HAA15–17. The deposition likely occurs because B2M has
high affinity for and binds preferentially to various types of
collagen18. The potential for B2M to be involved in cartilage
destruction is suggested by studies showing that it induces
synthesis of stromelysin (MMP-3) and cyclooxygenase-2
(COX-2) in human synovial fibroblasts12,19. Further support
derives from a recent study demonstrating that B2M
induces matrix metalloproteinase 1 (MMP-1) but not tissue
inhibitor of metalloproteinase 1 (TIMP-1) in osteoarthritic
synovial fibroblasts20. Thus, B2M appears likely to have a
destructive role in amyloidosis-related arthritis. Whether it
has a catabolic role in osteoarthritis (OA) remains
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HUMAN SYNOVIAL FLUID AND CARTILAGE SAMPLES
Human OA synovial fluid was aspirated and cartilage
samples were obtained from knee joints at arthroscopy or
total knee replacement. OA severity was graded according
to the system described by Marshall21. Briefly, each of the
six knee articular surfaces was assigned a cartilage grade
with points based on the worst lesion seen on each
particular surface. Grade 0 is normal (0 points), Grade I
cartilage is soft or swollen but the articular surface is intact
(1 point). In Grade II lesions, the cartilage surface is not
intact but the lesion does not extend down to subchondral
bone (2 points). Grade III damage extends to subchondral
bone but the bone is neither eroded nor eburnated (3
points). In Grade IV lesions, there is eburnation of or
erosion into bone (4 points). A global OA score is calculated
by summing the points from all six cartilage surfaces.
Based on the total score, each patient is then categorized
into one of four OA groups: mild (1–6), moderate (7–12),
marked (13–18), and severe (>18). Normal synovial fluid
samples were collected from volunteers with no history of
knee injury or arthritis. All synovial fluids were taken as
undiluted samples.
Human fetal femoral cartilage samples were collected
from a pool of aborted fetuses (8–12 weeks) and stored
immediately in liquid nitrogen. Human mild and severe OA
cartilage samples (graded as described above) were col-
lected at the time of arthroscopy or total knee replacement
and stored in liquid nitrogen immediately for subsequent
RNA isolation and RT–PCR analysis. For tissue culture,
severe OA cartilage samples were collected at the time of
total knee replacement and used immediately.RT–PCR
Pooled fetal, mild (six patients) or severe (three patients)
OA cartilage samples were subjected to total RNA extrac-
tion using TRIzol (GIBCO) reagent22. Reverse transcription
was carried out using 1 g total RNA with oligo-dT and
Superscript II reverse transcriptase (GIBCO). B2M specificprimers were designed at positions 167 and 581 in the B2M
nucleotide sequence (NM
–
004048). The forward primer is
between 167–186 (5′-CCA TCC GAC ATT GAA GTT GA-3′)
and the reverse primer is between 561–581 (5′-TGG AGC
AAC CTG CTC AGA TA-3′). This results in a PCR product
that is 415 bp in size. PCR reaction was carried out




002046) was used as an internal control for mRNA
amplification. The forward primer is 5′-TGG TAT CGT GGA
AGG ACT CAT-3′, and the reverse primer is 5′-GTG GGT
GTC GCT GTT GAA GTC-3′, giving a 370 bp size PCR
product.CARTILAGE ORGAN CULTURE
Human severe OA cartilage slices (∼10×12 mm2 surface
area/slice) were cultured at one slice/well in a 24-well plate
in DMEM (Dulbecco’s modified Eagle medium, GIBCO),
with 10% FCS (fetal calf serum, GIBCO), 100 units/ml
penicillin and 100 mg/ml streptomycin (GIBCO)
(DMEM+ +) at 37°C in a humidified atmosphere of 5%
CO223. Cultured medium (20 l) was then collected at
different time points for B2M ELISA.ELISA
B2M levels in synovial fluid and cartilage organ cultured
medium were measured using a beta-2 microglobulin
enzyme immunoassay test kit (ALPCO) according to the
provided protocol. Briefly, 10 l of sample or standard
controls (provided) were mixed with 1.0 ml sample diluent.
Subsequently, 5 l of the diluted samples and diluted
controls were placed into microtiter wells (96-well coated
with mouse monoclonal anti-human B2M antibody). After
applying the samples, 200 l of sample diluent was added
into each well and thoroughly mixed for 30 s at 200 rpm on
a plate rotator. The samples were then incubated at 37°C
for 30 min. The incubation mixture was then removed and
the wells were rinsed with running distilled water five times.
200 l of Enzyme Conjugate Reagent (sheep anti-human
B2M horseradish peroxidase conjugate) was then added
into each well, mixed gently for 10 s, and incubated at 37°C
for 30 min. The contents were then removed and the wells
were washed. 200 l of freshly mixed H2O2/TMB solution
was then added into each well, mixed for 10 s, and incu-
bated at room temperature in the dark for 20 min. The
reaction was stopped by adding 50 l stop solution (2N
HCl) to each well, mixed for 10 s and care taken to make
sure that all blue color changed to yellow color. Absorbance
was read at 450 nm with a microplate reader (BIO-TEK
Instruments). All measurements were done in duplicate.
A standard curve was plotted for each experiment. The
sample B2M concentration was determined by using the
mean absorbance of the sample to find the corresponding
concentration of B2M in g/ml on the standard curve.CELL CULTUREChondrocytes cultured for proliferation assay
Chondrocytes were retrieved from human severe OA
cartilage slices as previously described23. Cells were then
washed, counted and seeded at 1×104 cells/well in a
flat-bottomed 96-well plate (Corning) in DMEM+ +. Afterunknown. To date, most studies on B2M have focused on
its effects in synovial fibroblasts. There has been little work
exploring its potential effects on chondrocytes.
In our recent expressed sequence tags (ESTs) studies,
we found that B2M showed higher relative gene expression
levels in both mild and severe OA cartilage compared
to B2M expression in fetal and normal adult cartilage. It
was one of the most abundantly expressed genes in both
mild and severe OA cartilage cDNA libraries (unpublished
data). This observation stimulated our interest in further
investigating whether B2M may be involved in OA.
Our hypothesis is that B2M may be involved in OA
pathogenesis. The purpose of this study is to test whether
B2M may have functional effects on articular chondrocytes.
We first confirmed our initial B2M EST findings by assess-
ing B2M mRNA expression levels in OA cartilage using
RT–PCR. We then assessed for the in vivo presence of
B2M in OA synovial fluid, and detected the release of B2M
by OA cartilage in vitro. Importantly, we demonstrated that
B2M can have an inhibitory effect on chondrocyte prolifer-
ation. Chondrocyte genes regulated by B2M were identified
by microarray technology. Our findings suggest that B2M
could play a role in OA pathogenesis.
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only, and then incubated in DMEM with or without 10% FCS
along with different concentrations (0–10 g/ml) of B2M
(Sigma) for 48 h. Cell number in each well was then
determined by adding 10 l of WST-1 (a tetrazolium salt
that can be cleaved to formazan by mitochondrial dehydro-
genases in live cells, Roche) to each well, mixed thoroughly
for 1 min. and incubated at 37°C for 1.5 h. Then the plate
was scanned by a microplate autoreader (BIO-TEK Instru-
ments) at an absorbance of 450 nm. The number of viable
cells is reflected by the amount of formazan formed which
is quantified by measuring absorbance at 450 nm24. Exper-
iments were performed in triplicate and repeated with three
different severe OA cartilage samples.Chondrocytes cultured for microarray assay
Chondrocytes derived from severe OA cartilage were
seeded at 6.5×104/well (3.2×104/ml) in a 6-well plate
(Becton Dickinson). After cells attached to the plate,
they were washed with DMEM and cultured with DMEM
(no FCS), with or without 10 g/ml B2M for 72 h. After
incubation, cells were washed twice with GBSS (Gey’s
Balanced Salt Solution, GIBCO) and then subjected for
total RNA isolation with TRIzol reagent. RNA concentration
and quality were checked by measuring OD260/
OD280 nm, and gel electrophoresis.MICROARRAY ASSAYIn-house microarray slide preparation
PCR products (∼40 l) of 5184 cDNA clones derived
from cDNA libraries of mild and severe OA cartilage were
precipitated, washed and resuspended in 20 l 3×SSC.
Samples were then spotted in duplicate onto aminosilane
coated slides (25×75 mm, Corning) using a robotic GMS
417 arrayer (Genetic MicroSystems, MA). The size of
the array area was 18×36 mm. After spotting, slides
were rehydrated, heating blocked and UV crosslinked
(Stratagene, Stratalinker, 65 mJ). To prevent non-specific
probe binding, slides were treated as described by DeRisi
et al25,26.Probe preparation
Probes used for microarray hybridization were prepared
using the mRNA amplification method established by Wang
et al.27 with a few modifications. Briefly, 1 g total RNA was
used for first strand cDNA synthesis with oligo-dT (15)-T7
primer [5′-AAA CGA CGG CCA GTG AAT TGT AAT ACG
ACT CAC TAT AGG CGC T(15)-3′] and template switch
oligo primer (5′-AAG CAG TGG TAT CAA CGC AGA GTA
CGC GGG-3′). Second strand synthesis was carried out
with Advantage Polymerase Kit (Clontech). Double strand
cDNA was cleaned with Bio-6 Chromatograph column
(Bio-Rad). In vitro transcription for aRNA was done with T7
Megascript Kit (Ambion) and purified RNA with TRIzol
reagent. One microgram aRNA was used for second round
amplification. Three micrograms of amplified aRNA was
used for probe labeling by reverse transcription with 1 mM
Cy3 or Cy5 (Pharmacia).Hybridization
The protocol used for hybridization was based on that
provided by Hegde et al.28. Briefly, each slide was prehy-bridized with prehybridization buffer (5×SSC, 0.1% SDS
and 1% bovine serum albumin-Sigma) for 45 min at 42°C.
The hybridization solution was prepared as follows: Cy3
and Cy5 labeled probes were pooled together, 50 g
COT1-DNA (Life Technologies), 1 g Poly (A)-DNA(40–60)(Pharmacia) and 18 l 2×hybridization buffer (50% forma-
mide, 10×SSC, and 0.2% SDS) were added. This hybridi-
zation solution was then applied onto each prehybridized
microarray slide, avoiding air bubbles, and a cover-slip
(20×40 mm Corning) was placed on each slide. The slides
were then placed in a sealed hybridization chamber (Inter-
national Telechem) and 40 l H2O was added to the cham-
ber. The chamber was incubated in a 42°C water bath for
16–20 h. After hybridization, the slides were carefully
removed from the chamber and placed into a low-
stringency washing buffer (1×SSC, 0.2% SDS) at 42°C for
4 min. The cover-slips were gently removed from the
slides. The slides were then washed in a high-stringency
buffer (0.1×SSC, 0.2% SDS) at RT for 4 min. Finally, the
slides were washed in 0.1×SSC for 4 min and allowed to
air dry.Data collection and analysis
Each slide was scanned using a GMS 418 Array Scan-
ner (Genetic MicroSystems, MA), first in the Cy5 channel
and then the Cy3 channel. Data from each fluorescence
channel was collected and stored as a separate 16-bit TIFF
image. The images were then analysed using the ScanA-
lyze program29. The incorporated image (Cy5 and Cy3)
then underwent a gridding process, which allows for
manual adjustment of each grid for each spot. The fluor-
escence intensity and background-subtracted hybridization
intensity of each spot were collected. The ratio of measured
mean pixel intensities of Cy5 to Cy3 was calculated. To
identify differentially expressed genes, the data generated
must be normalized to adjust for differences in labeling and
detection efficiencies for the fluorescent labels. A linear
regression approach was used for normalization. This
approach assumes that for closely related samples, one
would expect many of the genes to be expressed at nearly
constant levels. Thus, a scatter plot of the measured Cy5
versus Cy3 intensities should have a slope of one. The
average of the ratios (Cy5/Cy3) of spots was calculated
and used to rescale the data and adjust the slope to one.
A post-normalization cut-off of two-fold up- or down-
regulation was used to define differentially expressed
genes28,30.STATISTICAL ANALYSIS
Statistical significance was assessed by Student’s t-test.
A P value less than 0.05 was considered significant.ResultsEXPRESSION OF B2M MRNA IN HUMAN FETAL, MILD AND SEVERE
OA CARTILAGE
Fetal, mild and severe OA cartilage samples were tested
for their B2M mRNA expression. The level of B2M mRNA
was determined by RT–PCR. Figure 1(a) shows that mild
and severe OA cartilage express similar levels of B2M, and
they are both higher than that found for fetal cartilage. This
result is consistent with our previous EST findings that B2M
Osteoarthritis and Cartilage Vol. 10, No. 12 953expression was significantly higher in mild (1.58%) and
severe OA (1.38%) than in fetal (0.04%) and normal adult
cartilage (0.50%), as shown in Fig. 1(b). Normal cartilage
samples were provided by the donor program at the
Department of Orthopaedics and Rehabilitation, University
of Miami. The samples were harvested within 12 h,
from the femoral condyle of patients who had died of
electrocution and blunt injuries.B2M LEVELS IN NORMAL AND OA SYNOVIAL FLUID
Elevated B2M levels in SF have been observed in most
rheumatoid arthritis patients20,31,32, however, the relative
level of B2M in osteoarthritic SF is not yet clear. A total of 55
SF samples were tested, the results of which are described
in Table I. The severity of OA was based on the total score
of the joint at the time of arthroscopy or total knee replace-
ment21. Figure 2 illustrates the average B2M levels
detected in normal, mild, moderate, marked and severe OA
SF. B2M levels in the synovial fluid from differing severitiesof OA are significantly higher than in the normal group
(P<0.05). However, there is no significant difference in B2M
levels between the differing OA severities.Fig. 1. B2M transcript levels in human fetal, normal adult, mild and
severe OA cartilage. (a) B2M mRNA expression in fetal, mild and
severe OA cartilage by RT-PCR. Pooled samples from fetal, mild
and severe OA cartilage were used to extract total RNA. 1 g RNA
was then used for reverse transcription and PCR amplification for
B2M and GAPDH, which gives 415 bp and 370 bp size PCR
product respectively. M=mild OA, S=severe OA cartilage, and
F=fetal cartilage. (b). Relative ESTs frequency levels of B2M in
fetal, normal adult, mild and severe OA cartilage cDNA libraries.
B2M EST copy number in each library was divided into the total
EST number of the corresponding library: fetal=6/13398=0.04%,
normal adult=88/17151=0.51%, mild OA=200/12651=1.58%,
severe OA=196/14222=1.38%.Table I
B2M levels in normal and osteoarthritic synovial fluid by ELISA.












Normal 0 9 17–36 (25) 0.69–1.27
(0.89±0.29)
Mild 1–6 11 24–66 (38) 1.00–5.49
(2.07±1.50)
Moderate 7–12 10 31–68 (47) 0.54–2.72
(1.68±0.60)
Marked 13–18 16 37–83 (64) 0.73–2.95
(1.72±0.68)
Severe >18 9 48–86 (68) 1.30–3.6
(2.32±0.72)Fig. 2. B2M levels in normal and OA synovial fluid detected by
ELISA. A total of 55 synovial fluid samples were tested using a
B2M enzyme immunoassay test kit. Ten microlitres of each sample
were measured in duplicate. B2M concentration was calculated
based on the standard curve. The average of B2M concentrations
in normal (nor, nine samples), mild (mioa, 11 samples), moderate
(mooa, 10 samples), marked (maoa, 16 samples) and severe
(seoa, 9 samples) was compared. Label * means that there is a
significant difference in B2M level compared to normal (P<0.05).SECRETION OF B2M BY OA CARTILAGE IN VITRO
To investigate if OA cartilage secretes B2M, an in vitro
cartilage organ culture was set up to detect B2M levels in
cultured medium. Severe OA cartilage slices were cultured
and medium was collected at different time points and
tested for B2M. Figure 3 shows that the release of B2M is
detectable in 24 h cultures and continues to increase
during the 72 h study period. Student t-test results show
that the B2M amount at 72 h is close to being statisticaly
significant (P=0.051). At the 72 h point, the B2M generated
was 2.1 g/g cartilage on average. The results were based
on three experimental runs, each using cartilage from a
different donor.
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B2M has been shown to have growth stimulating effects
on osteoblasts, but not on synovial fibroblasts12,33. To
investigate whether B2M has any effect on chondrocyte
proliferation, primary cultured human severe OA chondro-
cytes were incubated with increasing concentrations of
B2M in media with or without FCS for 48 h. Cell numbers
were then quantitatively estimated by their ability to cleave
WST-1, which is reflected as the absorbance at 450 nm. As
shown in Fig. 4, B2M did not stimulate chondrocyte prolifer-
ation. On the contrary, it showed an initial inhibitory effect at
1.0 g/ml, with the effect reaching significance at 10.0 g/
ml (no FCS group). There was no significant difference
observed among the B2M group treated with FCS,
although there seemed to be a decrease in cell number at
10.0 g/ml.B2M EFFECT ON OA CHONDROCYTE GENE EXPRESSION
Previous studies on B2M amyloidosis have suggested
that B2M is involved in cartilage destruction, as it induces
stromelysin and MMP-1 in human synovial fibro-
blasts12,19,20. Here, we used microarray technology to
detect chondrocyte genes regulated by B2M. Severe OA
chondrocytes were cultured with and without 10 g/ml B2M
in serum free media for 72 h. One microgram of total RNA
isolated from the cells (±B2M) was used for aRNA amplifi-
cation, fluoresence dye labeling and microarray hybrid-
ization. The DNA microarray contained duplicated 5184
cDNA elements, including 1842 known genes, 743 with no
significant match and 2599 ESTs.
The scatter plot (Fig. 5) shows the relative fluorescence
intensities in each of the two scanned channels. The ratio
between channel 2 (cy5, red) and channel 1 (cy3, green)
fluorescent intensities after normalization was used to
define differentially expressed genes. As shown in Fig. 5,most spots have a ratio close to 1.0, suggesting that the
expression of the genes they represent was not regulated
by B2M. Table II lists 131 genes, for example, that were
abundantly expressed by human severe OA chondrocytes
in primary culture. All of these genes have a fluorescence
level of at least 6000 pixel intensity in both B2M treated and
non-treated samples, and the ratio between the two
samples is between 0.8 and 1.2 which means their expres-
sion was not significantly altered by B2M. The list encom-
passes a variety of genes including 10 different
extracellular matrix proteins, 8 cytoskeletal proteins, 10
membrane protein/receptors, 17 transcription factors/zinc
finger proteins, 8 transport/carrier/channel proteins, 18 sig-
nal transduction related proteins, 6 nuclear proteins, 14
metabolism/protease genes, 2 genes for cell adhesion, one
growth factor, 22 ribosomal proteins, 2 translation related
genes, 2 ubiquitin/lysosomal genes and 11 other genes.
Genes up-regulated by B2M have a ratio >2, while
genes down-regulated by B2M have a ratio <0.5. Tables III
and IV list genes that were up- and down-regulated at least
two-fold by B2M (based on two experiments, with cross-
labeling, where non-B2M treated were labeled with Cy5
and B2M treated were labled with Cy3). There were twenty
genes found to be up-regulated by B2M, including three
matched ESTs, one matched genomic sequence, three
hypothetical proteins, and 13 known genes. YKL-39, colla-
gen type III, lumican, manganese superoxide dismutase
and SP-100 are some of the known genes that were
up-regulated by B2M. Eleven genes were found to be
down-regulated by B2M, of which four were matched ESTs.Fig. 3. B2M levels in cartilage organ cultured medium. Severe OA
cartilage slices were cultured in a 24-well plate at one piece/well.
10 l of medium was collected at 24 h, 48 h and 74 h culture
intervals and tested for cumulative release of B2M by ELISA. The
mean and standard deviation of three experiments were shown
(24 h: 1.03±0.35, 48 h: 1.42±0.37, 72 h: 2.03±0.9). Student t-test
results were: 24 h/48 h, P=0.359; 24 h/72 h, P=0.051; 48 h/72 h,
P=0.089.Fig. 4. B2M effect on human severe OA chondrocyte proliferation.
Chondrocytes were seeded at 1×104 cells/well in triplicate in a
96-well plate. Cells were cultured with or without FCS at various
concentrations of B2M (0, 0.1, 1.0, and 10.0 g/ml) for 48 h. Then
10 l of WST-1 (a tetrazolium salt that can be cleaved to formazan
by mitochondria dehydrogenases in live cells) was added to each
well and the plate was scanned by a microplate autoreader at an
absorbance of 450 nm. One of the three experiments with three
different severe OA donors was shown here. Label * means that
there is a significant difference between treated and non-treated
samples (0 g/ml B2M) (P<0.05).Discussion
B2M has been previously implicated as a potential
contributor to cartilage degradation. Our previous EST
studies on fetal, normal adult, mild and severe OA cartilage
showed that B2M has higher expression levels (over 1%) in
Osteoarthritis and Cartilage Vol. 10, No. 12 955Fig. 5. Scatter plot of fluorescent signal intensity from the hybridization to the microarray. The scatter plot was generated using Sigma Plot
5.0. The middle line represents a slope of one after normalization. The other two lines represent two-fold differential expression in channel
1 (Ch1 Cy3) and channel 2 (Ch2 Cy5).mild and severe OA cartilage than in normal adult and fetal
cartilage. However, there is only 0.2% difference in EST
frequency level between mild and severe OA. This EST
finding is confirmed by the RT–PCR results in which a
higher B2M mRNA expression levels are detected in mild
and severe OA cartilage. Our data suggests that B2M
mRNA is up-regulated in osteoarthritic chondrocytes. In
further support, our microarray result shows that B2M is
one of most abundantly expressed genes (with a fluor-
escence intensity of 2,4101) in primary cultured human
severe OA chondrocytes (Table II).
Elevated B2M levels have been observed in most rheu-
matoid arthritis SFs20,31,32. However, its level in osteoar-
thritic SF is not yet clear. We measured B2M levels in
osteoarthritic SF and found that on average it was signifi-
cantly higher in OA than in normal SF, regardless of OA
stage. Sample variations in B2M levels were observed in
OA (Table I). Age of the patient does not correlate to the
variation (data not shown). Since B2M is also elevated in
inflammatory conditions, the variation could in part be due
to varying severities of joint inflammation in differing OA
patients.
Potential sources for the B2M found in OA SF could be
serum, synoviocytes, inflammatory cells in SF or from
chondrocytes in articular cartilage. As we have demon-
strated that mild and severe OA cartilage express high
levels of B2M mRNA and secrete B2M protein in ex vivo
culture conditions, it is likely that OA chondrocytes, at least
in part, contribute to the elevated B2M levels we found in
OA SF.
The presence of B2M in osteoarthritic joints suggests
that B2M could potentially affect chondrocyte function. B2M
has been previously shown to stimulate osteoblast
growth33. However, it has no mitogenic effect on synovial
fibroblasts12. Our data indicates that B2M does not appear
to be a mitogen for osteoarthritic chondrocytes either. On
the contrary, it acts as an inhibitor of chondrocyte prolifer-
ation at high concentration (10.0 g/ml). This implies that
B2M may suppress chondrocyte proliferation.
To explore B2M’s potential effects on chondrocyte gene
expression, we applied a PCR-based cDNA microarray
approach. An in-house microarray was constructed usingcDNAs derived from mild and severe OA cartilage cDNA
libraries. The advantage of using the microarray is the
promise of rapid profiling of thousands of genes simul-
taneously. The inclusion of thousands of known genes as
well as novel ESTs in the array allows us to identify
previously unknown genes that may be important in OA
initiation and progression. In this study, we identified 131
known genes that were highly expressed in severe OA
chondrocytes. Concordantly, some of these genes have
also been reported to be highly expressed in osteoarthritic
cartilage through cDNA microarray and expressed
sequence tags studies34,35, such as, decorin, fibronectin,
COL1A2, COL6A3, osteonectin, and connective growth
factor. Furthermore, to reflect the differentiated status of
primary cultured chondrocytes, of these 131 identified
genes, some have just recently been reported to be highly
expressed in human fetal chondrocytes cultured in differ-
entiated condition, including ECM genes (e.g. decorin,
COL6A3, COL1A1, and COL11A1), cytoskeletal genes
(e.g. vimentin and tubulin), connective growth factor, and
ribosomal proteins (e.g. ribosomal protein S24 and L6)36.
More importantly, we have identified some genes that
have not been previously reported to be expressed by
chondrocytes, such as secreted frizzled-related protein 4
(SFRP4) and WDR1. Secreted frizzled-related proteins are
antagonists of the wnt (wingless)/fz (frizzled) receptors
pathway. The wnt/fz members influence cell proliferation,
differentiation and apoptosis37. Secreted frizzled-related
protein 2 is highly expressed in human severe OA chondro-
cytes, but not in normal cartilage chondrocytes38. SFRP4
has been implicated in human myocardium and suggested
to be involved in apoptosis37. To our knowledge, this is the
first report indicating that SFRP4 is expressed in human
severe OA chondrocytes. Given the possibility that SFRP4
could be involved in chondrocyte apoptosis, further
research needs to be focused on identifying its expression
patterns during OA progression and exploring its possible
role in OA pathogenesis.
To identify genes regulated by B2M, a two-fold cut-off
was applied. One interesting finding of our study is that
B2M regulates the expression of some extracellular matrix
proteins. Our study shows that B2M up-regulates the
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List of genes most abundantly expressed by human severe OA chondrocytes
Gene name ID Intensity R (Cy3/Cy5)
ECM
Decorin AF138300.1 27 281 1.0
Fibronectin 1 (FN1) Hs.287820 25 032 0.9
Collagen type VI, alpha 3 (COL6A3) X52022 14 955 0.9
Collagen type I, alpha 2 (COL1A2) NM
–
000089 13 303 0.9
Matrix Gla protein X53331 12 581 1.0
Hexabrachion X56160 12 400 1.1
Collagen type I, alpha 1 (COL1A1) AF017178.2 10 120 1.1
Collagen type XI, alpha 1 (COL11A1) J04177 9 245 1.2
Osteopontin D14813 8 089 1.0
Osteonectin J03040 6 454 1.2
Cytoskeletal
Actin, gamma X04098 39 095 1.1
Tubulin, alpha K00557 25 074 1.2
Vimentin Z19554 21 455 1.0
Actin, beta X00351 21 330 1.0
Transmembrane protein p63 Hs.74368 20 782 1.0
Actin related protein 2/3 complex, subunit 1A (41 Kd) Hs.90370 14 019 0.9
Actin binding protein ABP620 AB029290 10 711 1.2
Destrin Hs.82306 9 111 0.9
Membrane protein/receptors
Integrin beta-5 subunit J05633 19 714 0.9
IL-1 receptor antagonist IL-1Ra (IL-1RN) U65590 18 427 0.8
Platelet-derived growth factor receptor alpha (PDGFRA) M21574 16 660 0.8
Integrin beta 1 subunit X07979.1 12 069 0.9
Interleukin 1 receptor M27492 11 180 1.1
CD164 antigen, sialomucin Hs.43910 9 533 1.2
Epidermal growth factor receptor X00588 8 867 0.8
Interleukin 13 receptor, alpha 1 (IL13RA1) NM
–
001560 8 028 1.2
Melanoma-associated antigen ME491=CD63 Hs.76294 7 830 1.2
Integral membrane protein, calnexin, (IP90) L10284 6 641 1.2
Transcription related/zinc finger protein
Zinc finger transcriptional regulator (GOS24) M92844 26 192 1.0
MAFB/Kreisler basic region/leucine zipper transcription factor AF134157.1 23 289 1.0
Nuclear p68 protein (=DDX5) X15729 20 529 1.2
Kaiso (ZNF-kaiso) Hs.143604 16 670 1.2
Zinc finger protein 136 P52737 16 140 1.1
RNA binding motif protein 3 (RBM3) Hs.301404 15 945 0.8
Poly(A)-binding protein cytoplasmic 1 (PABPC1) XM
–
018280.1 14 749 0.9
CGI-99 protein Hs.110803 14 393 1.1
Zinc finger protein 258 Hs.301637 13 339 0.8
Poly(A)-binding protein (PABP) U68105 13 193 0.9
Zinc finger protein 85 NM
–
003429 11 663 0.8
Id-2H D13891 10 289 0.9
Nucleic acid binding protein sub2.3 Z29505 10 180 1.2
Nuclear factor NF-IL6 X52560.1 9 089 1.1
RING finger protein (ROC1) AF142059.1 6 997 0.8
Zinc finger protein 216 splice variant 2 (ZNF216) AF062347 6 097 1.2
Global transcription activator homologous sequence M88163 6 067 1.1
Transport/carrier/channel proteins
Lipocortin-V M21731 29 028 1.0
Annexin A2 NM
–
004039.1 17 626 1.0
ADP/ATP carrier protein (ANT-2) L78810 17 303 1.0
Voltage-dependent anion channel (VDAC1) g AF151097.1 10 940 1.1
Vacuolar H( )-ATPase subunit (ATP6GL) NM
–
004888.1 9 147 1.2
Chaperonin 10 U07550 7 420 1.1
Transmembrane glycoprotein (GPNMB) X76534 7 313 0.9
Connexin 43 Hs.74471 6 336 1.0
Signal transduction/G-protein related/kinase/phosphatase
Myristoylated alanine-rich protein kinase C substrate (80K-L) Hs.75607 25 603 1.0
Guanine nucleotide-binding protein alpha-subunit (G-s-alpha) M21142 23 783 0.8
Jk-recombination signal binding protein (RBPJK) L07872 16 395 0.9
Cysteine-rich, angiogenic inducer, 61 (CYR61) Hs.8867 16 264 0.9
Protein kinase C inhibitor-I U27143 15 933 1.1
Continued
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Gene name ID Intensity R (Cy3/Cy5)
Calmodulin (CALM1) U12022 13 830 1.0
Secreted frizzled-related protein 4 (SFRP4) Hs.105700 13 735 1.1
Unr-interacting protein (UNRIP) Hs.3727 10 132 1.1
X-linked phosphoglycerate kinase M11968 9 246 1.0
GSA alpha subunit of GsGTP binding protein X56009 8 716 1.0
GTP-binding protein Sara AF092130.1 8 372 1.0
G protein gamma-10 subunit U31383 8 291 1.1
Protein tyrosine kinase 9 Hs.82643 7 387 1.2
Diazepam binding inhibitor (DBI)=GABA receptor modulator Hs.78888 7 026 0.8
WDR1 protein=WD repeat domain 1 Hs.85100 6 992 1.2
Protein phosphatase 1 (PPP1R5) Y18207 6 830 0.8
SH3 domain-containing protein SH3P18 mRNA, Hs.348427 6 645 1.1
Coupling protein G(s) alpha subunit Z70769 6 008 1.2
Nuclear protein
hH3.3B gene for histone H3.3 Z48950 8 783 1.1
High mobility group-1 protein (HMG-1) X12597 11 704 1.0
Heterogeneous nuclear ribonucleoprotein K (HNRPK) S45523 6 586 1.0
hnRNP JKTBP Hs.170311 9 409 1.2
Sm protein G=Small nuclear ribonucleoprotein polypeptide G Hs.77496 7 599 1.1
SnRNP core protein Sm D2=Small nuclear ribonucleoprotein D2 polypeptide Hs.53125 8 501 0.9
Other
Beta 2-microglobulin AB021288 24 101 1.2
Smg GDS-associated protein SMAP=Kinesin-associated protein 3 Hs.171374 23 818 0.8
Clusterin Hs.75106 11 624 0.9
Apoferritin H Hs.62954 10 752 1.2
Heat shock protein (HSP89-alpha) M27024 10 287 1.0
ADP-ribosylation factor AF047432 10 136 0.9
Chitinase 3-like 2, Hs.154138 10 120 1.0
Heat shock protein 90 D87666 9 209 1.0
Complement component C1r J04080 7 875 1.2
Metallothionein-II (mt-II) Hs.118786 6 993 1.2
Selenoprotein P Hs.3314 6 127 1.1
Metabolism/protease
5′ nucleotidase X55740 24 902 1.0
HTRA serine protease (PRSS11) AF157623.1 27 839 1.0
Ferritin heavy chain Hs.62954 26 522 1.0
Cathepsin X U20280 15 967 1.1
Beta-hexosaminidase beta chain M19735 15 119 1.1
ATP-dependent metalloprotease YME1L AJ132637.1 15 037 1.1
Acid sphingomyelinase (ASM) M59917 10 625 0.9
PROS-27 Hs.74077 9 974 1.0
Cathepsin B L22569 9 820 1.0
Cystatin B Hs.695 8 748 1.1
Beta-migrating plasminogen activator inhibitor I M14083 8 642 1.1
NADH dehydrogenase X81900 7 799 0.9
Aldehyde dehydrogenase (ALD10) U46689 7 184 0.9
Malate dehydrogenase (MDHA) U20352 6 237 1.2
Cell adhesion
Catenin, beta X87838 12 725 0.9
Catenin, alphaE (CTNNA1) AF102803 6 246 1.2
Growth factor
Connective tissue growth factor (CTGF) Hs.75511 32 579 1.0
Translation related
Elongation factor 1 alpha subunit (EF-1 alpha) X03558 19 155 1.0
Eukaryotic translation initiation factor 2, subunit 2 (beta, 38 kD ) Hs.12163 6 618 1.1
Ribosomal protein
Ribosomal protein S24 M31520 38 231 0.9
Ribosomal protein L6 X69391 24 779 0.9
Ribosomal protein S11 X06617 23 613 1.2
Ribosomal protein S20 L06498 21 408 1.0
Ribosomal protein L37a L22154 18 784 1.0
Ribosomal protein L23a U43701.1 18 572 1.2
Ribosomal protein L17 X52839 17 849 1.1
Continued
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Gene name ID Intensity R (Cy3/Cy5)
Ribosomal protein L39 Hs.300141 16 083 1.0
Ribosomal protein S23 AB007158 15 422 1.0
Ribosomal protein L38 Z26876 13 027 0.9
Ribosomal protein S27a Hs.3297 11 900 1.1
Ribosomal protein L34 L38941 11 707 1.0
Ribosomal protein L7 X52967 11 697 0.8
Ribosomal protein S15a X84407 11 562 1.1
Ribosomal protein L9 U09953 10 835 0.9
Ribosomal protein S7 M77233 10 636 0.8
Ribosomal protein L26 L07287 10 629 0.9
Ribosomal protein L44 M15661 8 780 1.2
Ribosomal protein S27 NM
–
001030 8 389 0.9
Ribosomal protein L19 X63527 8 040 1.1
Ribosomal protein L21 U14967 6 362 1.1
Ribosomal protein L12 NM
–
000976 6 204 1.2
Ubiquitin/lysosomal
Epididymal secretory protein (19.5 kD) (HE1) Hs.119529 22 520 1.2
Ubiquitin-conjugating enzyme E2B (UBE2B) NM
–
003337 12 987 1.0
Note: ID=Genbank accession number or UniGene reference number, Pixel Intensity=average fluorescence level of Cy3-labeled cDNA
from B2M-treated chondrocytes and Cy5-labeled cDNA from non-treated chondrocytes, R=Cy3 (B2M-treated)/Cy5 (non-treated),
ECM=extracellular matrix.Table III





Acyl-coenzyme A:cholesterol acyltransferase 2.5 Hs.14553
Adrenomedullin 2.3 S73906
Chitinase precursor=YKL-39 2.8 Hs.154138
Collagen type III, alpha 1 4.3 Hs.119571
DNA sequence clone RP11-27N17 2.3 AC021801
EST (ah53c02.s1) 2.1 Hs.31819
EST (ts23b10.x1) 3.0 Hs.118446
EST(zf50c04.s1) 2.0 Hs.77550
Hypothetical protein 3.2 AL035369
Hypothetical protein CGI-110 2.5 Hs.177861
Hypothetical protein (DKFZp564H122) 3.6 Hs.28783
Lumican 2.3 Hs.79914
MAD-3 (IkB-like activity) 2.6 Hs.81328
Manganese superoxide dismutase (SOD-2) 2.1 X65965
Nicotinamide N-methyltransferase (NNMT) 3.2 Hs.76669
Nuclear autoantigen (SP-100) 28.0 Hs.77617
Syntaxin 4 binding protein UNC-18c 7.0 Hs.8813
Syntaxin 7 3.8 Hs.8906
Transforming growth factor-beta induced gene product (BIGH3) 3.6 Hs.118787
Translational inhibitor protein p14.5 2.3 Hs.18426
Alphabetical list of genes showing at least two-fold differential expression in B2M treated chondrocytes (two
experiments).expression of COL3A1 and lumican, whereas it down-
regulates the expression of asporin. We also confirmed
these findings by real-time RT–PCR with two different
severe OA samples treated with either 5 g/ml or 10 g/ml
B2M (data not shown). Collagen type III has been pre-
viously reported to be highly expressed in severe OA
cartilage and in cultured chondrocytes39. This suggests
that B2M may play a role in modulating collagen gene
expression in osteoarthritic chondrocytes. Asporin is a
recently identified leucine-rich repeat family protein which
is closely related to decorin and biglycan40. Its mRNA has
been shown to be highly expressed in human osteoarthriticcartilage40. The function of this protein is not yet clear,
though it has been suggested to be involved in stabilizing
the collagen network40. Thus, down-regulation of asporin
by B2M raises the possibility that B2M could affect the
integrity of collagen matrix.
Another gene up-regulated by B2M is YKL-39, a recently
cloned novel chondrocyte protein that is closely related to
YKL-40, a member of the chitinase protein family41. How-
ever, YKL-39 lacks the essential active glutamate site for
chitinase activity41. Its function in normal chondrocytes is
not yet clear and the importance of its up-regulation by B2M
in severe OA chondrocytes warrants further investigation.
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EST (yx42g01.s1) 2.0 Hs.19280
EST (nz94a11.s1) 4.0 AA730269
EST (zr99b03.r1) 2.4 Hs.14456
EST (zw78b10.r1) 2.0 Hs.70333
Hypothetical protein (KIAA0102) 2.7 Hs.77665
Intersectin short form 2.4 Hs.66392
KARP-1-binding protein 2 (KAB2) 2.3 Hs.25132
Membrane protein 2.0 Hs.93832
Peripheral myelin protein 22 (PMP22) 2.1 Hs.103724
Putative GTP-binding protein 2.8 AJ006412
Alphabetical list of genes down-regulated at least two-fold by B2M in OA chondrocytes (two experiments).The potential catabolic role for B2M in cartilage degra-
dation is suggested by its ability to induce stromelysin and
MMP-1 synthesis in human synovial fibroblasts12,19,20.
Notably, we did not find a change in stromelysin expression
in chondrocytes, suggesting that B2M’s effect is cell-
specific.
Of the genes regulated by B2M, seven unknown genes
(hypothetical/ESTs/DNA matches) were up-regulated and
five were down-regulated. Future challenges would include
(1) to assess if the same set of genes or some subset are
regulated by B2M in a similar pattern in different OA staged
patients, and (2) to determine their functional roles in
chondrocytes.
The mechanisms underlying B2M’s potential effects on
OA appear to be somewhat different from those proposed
for amyloidosis-related arthritis. In amyloidosis-related
arthritis, the source of B2M is mainly from serum, and due
to its high affinity to collagen, it deposits in the joint. B2M
subsequently stimulates synovial cells to produce colla-
genase (e.g. stromelysin) which in turn causes local tissue
destruction12,42. However, in OA, B2M is up-regulated in
osteoarthritic chondrocytes. This local effect in chondro-
cytes may directly influence their proliferation and collagen
production. Furthermore, the release of B2M into synovial
fluid from chondrocytes could indirectly alter synovial cell
function in the same way as in amyloidosis-related arthritis.
Before we can answer how critical B2M is in OA onset
and progression, we need to confirm these findings with
multiple OA donors (e.g. different OA stages and different
age group patients) and better understand the functions
of those genes that are up- or down-regulated by B2M
in OA.
In conclusion, the results show that B2M is highly
expressed in human OA chondrocytes, and can be
secreted by OA cartilage explant in vitro. B2M levels in
human OA synovial fluids are significantly higher than in
normal synovial fluid. Also, B2M can have an inhibitory
effect on chondrocyte proliferation in culture. Our data also
show that B2M affects the expression of numerous genes
in chondrocytes. It up-regulates genes like collagen type III,
YKL-39 and SOD-2. These results suggest that B2M might
be involved in the pathogenesis of OA.Acknowledgments
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